カテゴリー： 世界, 医療/バイオ, GlobalInfoResearch

世界のメチシリン耐性黄色ブドウ球菌感染症治療薬市場2023年：企業・地域・タイプ・用途別分析

【英語タイトル】Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

GlobalInfoResearchが出版した調査資料（GIR23AG11460）・商品コード：GIR23AG11460
・発行会社（調査会社）：GlobalInfoResearch
・発行日：2023年8月
・ページ数：92
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（注文後2-3日）
・調査対象地域：グローバル
・産業分野：医薬品＆ヘルスケア
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,480 ⇒換算￥528,960見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,220 ⇒換算￥793,440見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）USD6,960 ⇒換算￥1,057,920見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

GlobalInfoResearchの最新の調査によると、世界のメチシリン耐性黄色ブドウ球菌感染症治療薬の市場規模は2022年のxxx米ドルから2029年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を考慮しながら市場規模を推計しました。
このレポートは、世界のメチシリン耐性黄色ブドウ球菌感染症治療薬市場に関する詳細かつ包括的な分析の結果です。定量的分析と定性的分析データが、メーカー別、地域別、国別、タイプ別、用途別に記載されています。

市場は常に変化しているため、本レポートでは、競争、需要と供給の傾向、および多くの市場にわたる需要の変化に影響する主要な要因を調査しました。主要な競合他社の企業概要と製品例、および2023年の市場シェア予測も記載しました。

本レポートの主な目的は次のとおりです。
- 世界および主要国の市場機会の規模を決定するため
- メチシリン耐性黄色ブドウ球菌感染症治療薬の成長可能性を評価するため
- 各製品および最終用途市場の将来の成長を予測するため
- 市場に影響を与える競争要因を評価するため

メチシリン耐性黄色ブドウ球菌感染症治療薬市場はタイプと用途によって区分されます。2018年～2029年において、量と金額の観点からタイプ別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

タイプ別セグメント
・リポペプチド、オキサゾリジノン、テトラサイクリン、セファロスポリン、リポ糖ペプチド、葉酸拮抗薬、その他

用途別セグメント
・病院、専門クリニック、その他

主要な市場プレーヤー
・Basilea Pharmaceutica Ltd、The Medicines Company、Theravance Biopharma、Allergan、Merck & Co., Inc、Pfizer, Inc

地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、メチシリン耐性黄色ブドウ球菌感染症治療薬製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要なメチシリン耐性黄色ブドウ球菌感染症治療薬メーカーの企業概要、2019年～2022年までのメチシリン耐性黄色ブドウ球菌感染症治療薬の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要なメチシリン耐性黄色ブドウ球菌感染症治療薬メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2018年～2029年までの地域別メチシリン耐性黄色ブドウ球菌感染症治療薬の販売量、売上、成長性を示しています。
・第5、6章では、2018年～2029年までのメチシリン耐性黄色ブドウ球菌感染症治療薬のタイプ別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2018年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2029年までの主要地域でのメチシリン耐性黄色ブドウ球菌感染症治療薬市場予測を収録しています。
・第12章では、市場力学、成長要因、阻害要因、トレンド、ポーターズファイブフォース分析、新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を掲載しています。
・第13章では、主要な原材料、主要なサプライヤー、およびメチシリン耐性黄色ブドウ球菌感染症治療薬の産業チェーンを掲載しています。
・第14、15章では、メチシリン耐性黄色ブドウ球菌感染症治療薬の販売チャネル、販売業者、顧客、調査結果について説明します。

・市場概要
– メチシリン耐性黄色ブドウ球菌感染症治療薬の概要
– タイプ別分析（2018年vs2022年vs2029年）：リポペプチド、オキサゾリジノン、テトラサイクリン、セファロスポリン、リポ糖ペプチド、葉酸拮抗薬、その他
– 用途別分析（2018年vs2022年vs2029年）：病院、専門クリニック、その他
– 世界のメチシリン耐性黄色ブドウ球菌感染症治療薬市場規模・予測
– 世界のメチシリン耐性黄色ブドウ球菌感染症治療薬生産能力分析
– 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
– Basilea Pharmaceutica Ltd、The Medicines Company、Theravance Biopharma、Allergan、Merck & Co., Inc、Pfizer, Inc
・メーカー別市場シェア・市場集中度
・地域別市場分析2018年-2029年
・タイプ別分析2018年-2029年：リポペプチド、オキサゾリジノン、テトラサイクリン、セファロスポリン、リポ糖ペプチド、葉酸拮抗薬、その他
・用途別分析2018年-2029年：病院、専門クリニック、その他
・メチシリン耐性黄色ブドウ球菌感染症治療薬の北米市場
– タイプ別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：アメリカ、カナダ、メキシコなど
・メチシリン耐性黄色ブドウ球菌感染症治療薬のヨーロッパ市場
– タイプ別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・メチシリン耐性黄色ブドウ球菌感染症治療薬のアジア市場
– タイプ別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・メチシリン耐性黄色ブドウ球菌感染症治療薬の南米市場
– タイプ別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：ブラジル、アルゼンチンなど
・メチシリン耐性黄色ブドウ球菌感染症治療薬の中東・アフリカ市場
– タイプ別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・市場力学（成長要因、阻害要因、トレンド、ポーターズファイブフォース分析）
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

1 Market Overview
1.1 Product Overview and Scope of Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Lipopeptide
1.3.3 Oxazolidinone
1.3.4 Tetracycline
1.3.5 Cephalosporin
1.3.6 Lipoglycopeptide
1.3.7 Folate Antagonist
1.3.8 Other
1.4 Market Analysis by Application
1.4.1 Overview: Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospital
1.4.3 Specialist Clinic
1.4.4 Other
1.5 Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Market Size & Forecast
1.5.1 Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity (2018-2029)
1.5.3 Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Average Price (2018-2029)
2 Manufacturers Profiles
2.1 Basilea Pharmaceutica Ltd
2.1.1 Basilea Pharmaceutica Ltd Details
2.1.2 Basilea Pharmaceutica Ltd Major Business
2.1.3 Basilea Pharmaceutica Ltd Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Product and Services
2.1.4 Basilea Pharmaceutica Ltd Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Basilea Pharmaceutica Ltd Recent Developments/Updates
2.2 The Medicines Company
2.2.1 The Medicines Company Details
2.2.2 The Medicines Company Major Business
2.2.3 The Medicines Company Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Product and Services
2.2.4 The Medicines Company Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 The Medicines Company Recent Developments/Updates
2.3 Theravance Biopharma
2.3.1 Theravance Biopharma Details
2.3.2 Theravance Biopharma Major Business
2.3.3 Theravance Biopharma Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Product and Services
2.3.4 Theravance Biopharma Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Theravance Biopharma Recent Developments/Updates
2.4 Allergan
2.4.1 Allergan Details
2.4.2 Allergan Major Business
2.4.3 Allergan Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Product and Services
2.4.4 Allergan Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Allergan Recent Developments/Updates
2.5 Merck & Co., Inc
2.5.1 Merck & Co., Inc Details
2.5.2 Merck & Co., Inc Major Business
2.5.3 Merck & Co., Inc Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Product and Services
2.5.4 Merck & Co., Inc Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Merck & Co., Inc Recent Developments/Updates
2.6 Pfizer, Inc
2.6.1 Pfizer, Inc Details
2.6.2 Pfizer, Inc Major Business
2.6.3 Pfizer, Inc Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Product and Services
2.6.4 Pfizer, Inc Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Pfizer, Inc Recent Developments/Updates
3 Competitive Environment: Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug by Manufacturer
3.1 Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity by Manufacturer (2018-2023)
3.2 Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue by Manufacturer (2018-2023)
3.3 Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Manufacturer Market Share in 2022
3.4.2 Top 6 Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Manufacturer Market Share in 2022
3.5 Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Market: Overall Company Footprint Analysis
3.5.1 Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Market: Region Footprint
3.5.2 Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Market: Company Product Type Footprint
3.5.3 Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Market Size by Region
4.1.1 Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity by Region (2018-2029)
4.1.2 Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value by Region (2018-2029)
4.1.3 Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Average Price by Region (2018-2029)
4.2 North America Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value (2018-2029)
4.3 Europe Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value (2018-2029)
4.4 Asia-Pacific Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value (2018-2029)
4.5 South America Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value (2018-2029)
4.6 Middle East and Africa Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity by Type (2018-2029)
5.2 Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value by Type (2018-2029)
5.3 Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity by Application (2018-2029)
6.2 Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value by Application (2018-2029)
6.3 Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Average Price by Application (2018-2029)
7 North America
7.1 North America Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity by Type (2018-2029)
7.2 North America Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity by Application (2018-2029)
7.3 North America Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Market Size by Country
7.3.1 North America Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity by Country (2018-2029)
7.3.2 North America Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity by Type (2018-2029)
8.2 Europe Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity by Application (2018-2029)
8.3 Europe Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Market Size by Country
8.3.1 Europe Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity by Country (2018-2029)
8.3.2 Europe Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Market Size by Region
9.3.1 Asia-Pacific Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity by Type (2018-2029)
10.2 South America Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity by Application (2018-2029)
10.3 South America Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Market Size by Country
10.3.1 South America Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity by Country (2018-2029)
10.3.2 South America Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Market Size by Country
11.3.1 Middle East & Africa Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Market Drivers
12.2 Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Market Restraints
12.3 Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug and Key Manufacturers
13.2 Manufacturing Costs Percentage of Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug
13.3 Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Production Process
13.4 Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Typical Distributors
14.3 Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer

List of Tables
Table 1. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Basilea Pharmaceutica Ltd Basic Information, Manufacturing Base and Competitors
Table 4. Basilea Pharmaceutica Ltd Major Business
Table 5. Basilea Pharmaceutica Ltd Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Product and Services
Table 6. Basilea Pharmaceutica Ltd Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Basilea Pharmaceutica Ltd Recent Developments/Updates
Table 8. The Medicines Company Basic Information, Manufacturing Base and Competitors
Table 9. The Medicines Company Major Business
Table 10. The Medicines Company Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Product and Services
Table 11. The Medicines Company Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. The Medicines Company Recent Developments/Updates
Table 13. Theravance Biopharma Basic Information, Manufacturing Base and Competitors
Table 14. Theravance Biopharma Major Business
Table 15. Theravance Biopharma Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Product and Services
Table 16. Theravance Biopharma Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Theravance Biopharma Recent Developments/Updates
Table 18. Allergan Basic Information, Manufacturing Base and Competitors
Table 19. Allergan Major Business
Table 20. Allergan Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Product and Services
Table 21. Allergan Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Allergan Recent Developments/Updates
Table 23. Merck & Co., Inc Basic Information, Manufacturing Base and Competitors
Table 24. Merck & Co., Inc Major Business
Table 25. Merck & Co., Inc Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Product and Services
Table 26. Merck & Co., Inc Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Merck & Co., Inc Recent Developments/Updates
Table 28. Pfizer, Inc Basic Information, Manufacturing Base and Competitors
Table 29. Pfizer, Inc Major Business
Table 30. Pfizer, Inc Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Product and Services
Table 31. Pfizer, Inc Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Pfizer, Inc Recent Developments/Updates
Table 33. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 34. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Revenue by Manufacturer (2018-2023) & (USD Million)
Table 35. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 36. Market Position of Manufacturers in Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 37. Head Office and Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Production Site of Key Manufacturer
Table 38. Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Market: Company Product Type Footprint
Table 39. Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Market: Company Product Application Footprint
Table 40. Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug New Market Entrants and Barriers to Market Entry
Table 41. Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Mergers, Acquisition, Agreements, and Collaborations
Table 42. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity by Region (2018-2023) & (K Units)
Table 43. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity by Region (2024-2029) & (K Units)
Table 44. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value by Region (2018-2023) & (USD Million)
Table 45. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value by Region (2024-2029) & (USD Million)
Table 46. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Average Price by Region (2018-2023) & (US$/Unit)
Table 47. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Average Price by Region (2024-2029) & (US$/Unit)
Table 48. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 49. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 50. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value by Type (2018-2023) & (USD Million)
Table 51. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value by Type (2024-2029) & (USD Million)
Table 52. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Average Price by Type (2018-2023) & (US$/Unit)
Table 53. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Average Price by Type (2024-2029) & (US$/Unit)
Table 54. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 55. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 56. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value by Application (2018-2023) & (USD Million)
Table 57. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value by Application (2024-2029) & (USD Million)
Table 58. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Average Price by Application (2018-2023) & (US$/Unit)
Table 59. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Average Price by Application (2024-2029) & (US$/Unit)
Table 60. North America Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 61. North America Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 62. North America Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 63. North America Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 64. North America Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity by Country (2018-2023) & (K Units)
Table 65. North America Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity by Country (2024-2029) & (K Units)
Table 66. North America Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value by Country (2018-2023) & (USD Million)
Table 67. North America Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value by Country (2024-2029) & (USD Million)
Table 68. Europe Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 69. Europe Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 70. Europe Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 71. Europe Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 72. Europe Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity by Country (2018-2023) & (K Units)
Table 73. Europe Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity by Country (2024-2029) & (K Units)
Table 74. Europe Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value by Country (2018-2023) & (USD Million)
Table 75. Europe Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value by Country (2024-2029) & (USD Million)
Table 76. Asia-Pacific Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 77. Asia-Pacific Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 78. Asia-Pacific Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 79. Asia-Pacific Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 80. Asia-Pacific Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity by Region (2018-2023) & (K Units)
Table 81. Asia-Pacific Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity by Region (2024-2029) & (K Units)
Table 82. Asia-Pacific Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value by Region (2018-2023) & (USD Million)
Table 83. Asia-Pacific Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value by Region (2024-2029) & (USD Million)
Table 84. South America Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 85. South America Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 86. South America Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 87. South America Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 88. South America Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity by Country (2018-2023) & (K Units)
Table 89. South America Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity by Country (2024-2029) & (K Units)
Table 90. South America Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value by Country (2018-2023) & (USD Million)
Table 91. South America Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value by Country (2024-2029) & (USD Million)
Table 92. Middle East & Africa Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 93. Middle East & Africa Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 94. Middle East & Africa Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 95. Middle East & Africa Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 96. Middle East & Africa Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity by Region (2018-2023) & (K Units)
Table 97. Middle East & Africa Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity by Region (2024-2029) & (K Units)
Table 98. Middle East & Africa Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value by Region (2018-2023) & (USD Million)
Table 99. Middle East & Africa Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value by Region (2024-2029) & (USD Million)
Table 100. Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Raw Material
Table 101. Key Manufacturers of Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Raw Materials
Table 102. Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Typical Distributors
Table 103. Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Typical Customers
List of Figures
Figure 1. Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Picture
Figure 2. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value Market Share by Type in 2022
Figure 4. Lipopeptide Examples
Figure 5. Oxazolidinone Examples
Figure 6. Tetracycline Examples
Figure 7. Cephalosporin Examples
Figure 8. Lipoglycopeptide Examples
Figure 9. Folate Antagonist Examples
Figure 10. Other Examples
Figure 11. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 12. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value Market Share by Application in 2022
Figure 13. Hospital Examples
Figure 14. Specialist Clinic Examples
Figure 15. Other Examples
Figure 16. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 17. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 18. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity (2018-2029) & (K Units)
Figure 19. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Average Price (2018-2029) & (US$/Unit)
Figure 20. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity Market Share by Manufacturer in 2022
Figure 21. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value Market Share by Manufacturer in 2022
Figure 22. Producer Shipments of Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 23. Top 3 Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Manufacturer (Consumption Value) Market Share in 2022
Figure 24. Top 6 Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Manufacturer (Consumption Value) Market Share in 2022
Figure 25. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity Market Share by Region (2018-2029)
Figure 26. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value Market Share by Region (2018-2029)
Figure 27. North America Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value (2018-2029) & (USD Million)
Figure 28. Europe Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value (2018-2029) & (USD Million)
Figure 29. Asia-Pacific Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value (2018-2029) & (USD Million)
Figure 30. South America Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value (2018-2029) & (USD Million)
Figure 31. Middle East & Africa Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value (2018-2029) & (USD Million)
Figure 32. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity Market Share by Type (2018-2029)
Figure 33. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value Market Share by Type (2018-2029)
Figure 34. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Average Price by Type (2018-2029) & (US$/Unit)
Figure 35. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity Market Share by Application (2018-2029)
Figure 36. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value Market Share by Application (2018-2029)
Figure 37. Global Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Average Price by Application (2018-2029) & (US$/Unit)
Figure 38. North America Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity Market Share by Type (2018-2029)
Figure 39. North America Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity Market Share by Application (2018-2029)
Figure 40. North America Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity Market Share by Country (2018-2029)
Figure 41. North America Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value Market Share by Country (2018-2029)
Figure 42. United States Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 43. Canada Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 44. Mexico Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 45. Europe Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity Market Share by Type (2018-2029)
Figure 46. Europe Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity Market Share by Application (2018-2029)
Figure 47. Europe Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity Market Share by Country (2018-2029)
Figure 48. Europe Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value Market Share by Country (2018-2029)
Figure 49. Germany Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 50. France Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 51. United Kingdom Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 52. Russia Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 53. Italy Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 54. Asia-Pacific Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity Market Share by Type (2018-2029)
Figure 55. Asia-Pacific Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity Market Share by Application (2018-2029)
Figure 56. Asia-Pacific Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity Market Share by Region (2018-2029)
Figure 57. Asia-Pacific Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value Market Share by Region (2018-2029)
Figure 58. China Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. Japan Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 60. Korea Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 61. India Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 62. Southeast Asia Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 63. Australia Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 64. South America Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity Market Share by Type (2018-2029)
Figure 65. South America Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity Market Share by Application (2018-2029)
Figure 66. South America Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity Market Share by Country (2018-2029)
Figure 67. South America Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value Market Share by Country (2018-2029)
Figure 68. Brazil Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 69. Argentina Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 70. Middle East & Africa Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity Market Share by Type (2018-2029)
Figure 71. Middle East & Africa Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity Market Share by Application (2018-2029)
Figure 72. Middle East & Africa Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Sales Quantity Market Share by Region (2018-2029)
Figure 73. Middle East & Africa Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value Market Share by Region (2018-2029)
Figure 74. Turkey Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 75. Egypt Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 76. Saudi Arabia Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 77. South Africa Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 78. Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Market Drivers
Figure 79. Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Market Restraints
Figure 80. Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Market Trends
Figure 81. Porters Five Forces Analysis
Figure 82. Manufacturing Cost Structure Analysis of Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug in 2022
Figure 83. Manufacturing Process Analysis of Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug
Figure 84. Methicillin-Resistant Staphylococcus Aureus Infection Treatment Drug Industrial Chain
Figure 85. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 86. Direct Channel Pros & Cons
Figure 87. Indirect Channel Pros & Cons
Figure 88. Methodology
Figure 89. Research Process and Data Source


★調査レポート[世界のメチシリン耐性黄色ブドウ球菌感染症治療薬市場2023年：企業・地域・タイプ・用途別分析] (コード：GIR23AG11460)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界のメチシリン耐性黄色ブドウ球菌感染症治療薬市場2023年：企業・地域・タイプ・用途別分析]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界のメチシリン耐性黄色ブドウ球菌（MRSA）検査システム市場予測2023-2029：免疫診断学、分子診断学
  • 世界の鼻咽頭スワブ市場2023-2031：用途別（インフルエンザ、新型コロナウイルス感染症、呼吸器合胞体ウイルス、百日咳菌感染症、MRSA（メチシリン耐性黄色ブドウ球菌）、その他）
  • 世界の抗菌薬耐性診断市場（～2030年）：病原体別（薬剤耐性レンサ球菌、薬剤耐性肺炎球菌（DRSP）、メチシリン耐性黄色ブドウ球菌、クロストリジウム・ディフィシル（CD）、薬剤耐性淋菌（DRNG）、薬剤耐性サルモネラ（DRNTS）、その他）、技術別、エンドユーザー別、地域別
  • 世界の感染防止用高度創傷被覆材市場2023年：企業・地域・タイプ・用途別分析
  • 世界の耐放射線光ファイバコネクタ市場2023年：企業・地域・タイプ・用途別分析
  • 世界の耐衝撃サーメット市場2023年：企業・地域・タイプ・用途別分析

    • ◆H&Iグローバルリサーチのお客様（例）◆